two dimensional speckle tracking echocardiography predicts preclinical cardiotoxicity in breast...
TRANSCRIPT
![Page 1: TWO DIMENSIONAL SPECKLE TRACKING ECHOCARDIOGRAPHY PREDICTS PRECLINICAL CARDIOTOXICITY IN BREAST CANCER PATIENTS](https://reader031.vdocuments.us/reader031/viewer/2022020619/575097ed1a28abbf6bd7bacc/html5/thumbnails/1.jpg)
Heart Failure and Cardiomyopathies
A829JACC April 1, 2014
Volume 63, Issue 12
two diMenSional Speckle tracking echocardiography predictS preclinical cardiotoxicity in breaSt cancer patientS
Poster ContributionsHall CSaturday, March 29, 2014, 3:45 p.m.-4:30 p.m.
Session Title: Heart Failure and Cardiomyopathies: Diagnostic, Prognostic and Therapeutic Strategies in CardiomyopathiesAbstract Category: 12. Heart Failure and Cardiomyopathies: ClinicalPresentation Number: 1147-183
Authors: Nicole Sandhu, Jocelyn Spoon, Joerg Herrmann, Patricia Pellikka, Hector R Villarraga, Mayo Clinic, Rochester, MN, USA
background: Changes in two dimensional speckle tracking echocardiography (2D-STE) may identify women at risk for cardiotoxicity during breast cancer treatment prior to left ventricular ejection fraction (LVEF) changes. Cardiotoxicity is defined as a drop in LVEF to < 50% or an absolute decrease of 10% on a follow-up echocardiogram (event group).
Methods: We identified 41 women (54 ± 13 yrs) who received anthracyclines and trastuzumab at our institution for whom echocardiograms were available for analysis. Pretreatment and first on-treatment echocardiograms were analyzed with 2D-STE to evaluate whether a change in longitudinal, circumferential or radial strain and systolic and early diastolic strain rate could predict subsequent cardiotoxicity. Images were exported to the velocity vector imaging station for off-line analysis. ANOVA ROC and AUC analysis was performed. All patients had a normal pre-treatment LVEF .
results: The event group had an average LVEF of 66.6 ± 5.2 pretreatment (T0) and 58.6 ± 9.8% early on-treatment (T1) versus 64.5 ± 4% at T0 and 63 ± 4.2% at T1 in the non-event group. Short axis early strain rate (SAX SRe) at T0 (AUC 0.7; cutoff 1.52; sensitivity 67%; specificity 61%; p<0.02), 2-chamber view strain (2CS) at T1 (AUC 0.7; cutoff -17.5; sensitivity 78%; specificity 64%; p<0.03), global longitudinal strain (GLS) at T1 (AUC 0.7; cutoff -12.9; sensitivity 95%; specificity 41%; p<0.03) and early diastolic longitudinal strain rate (LSRe) (AUC 0.7; cutoff 1.13; sensitivity 94%; specificity 50%; p<0.01) were individually associated with subsequent cardiotoxic events. Combining SAX SRe with GLS (AUC 0.81; sensitivity 94%; specificity 65%; p=0.002) was the strongest indicator of subsequent on treatment cardiotoxicity. Combining SAX SRe with 2CS (AUC 0.8; sensitivity 94%; specificity 60%; p<0.03) or LSRe (AUC 0.79; sensitivity 72%; specificity (80%0; p<0.01) were also significant predictors.
conclusions: Our data suggests that pre-treatment SAX SRe and the combination of pretreatment SAX SRe and GLS during early follow-up can predict on-treatment cardiotoxicity prior to a significant drop in LVEF. A larger cohort and prospective testing is needed to confirm these findings.